Background. The therapeutic management of psoriasis includes conventional treatments as well as the new generation of highly effective TNF-alpha inhibitors. However, psoriasis has proven to be a complex therapeutic challenge and treatment failures are not uncommon. Thus, laboratory biomarkers of disease progression/therapeutic efficacy may greatly help in the clinical management of psoriasis. Aims. To identify laboratory biomarkers for clinical management and therapeutic monitoring of psoriasis. Methods. An observational study performed on 59 patients, presenting moderate to severe psoriasis, undergoing treatment with anti-TNF-alpha agents (etanercept, adalimumab, and infliximab). Soluble and cellular immune/inflammatory parameters were assessed at baseline and after 12 and 24 weeks of treatment. Results. Clinical efficacy was achieved in 88% of the subjects at 12 weeks, reaching 90% after 24 weeks. IL-6 and IL-22, which were elevated at baseline, were significantly reduced, in association with a significant decrease of CLA+ T cells and an increase of Treg lymphocytes. T, B, and NK cell subsets and T cell response to recall antigens did not show any evidence of immune suppression. Conclusions. Immune/inflammatory parameters including IL-6 and IL-22, CLA+ T cells, and Treg lymphocytes may prove to be valuable laboratory tools for the clinical and therapeutic monitoring of psoriasis.

Cordiali-fei, P., Bianchi, L., Bonifati, C., Trento, E., Ruzzetti, M., Francesconi, F., Bultrini, S., D'agosto, G., Bordignon, V., Francavilla, V., Tripiciano, A., Chiricozzi, A., Campione, E., Cavallotti, C., Orlandi, A., Berardesca, E., Di Carlo, A., Chimenti, S., Ensoli, F., Immunologic biomarkers for clinical and therapeutic management of psoriasis, <<MEDIATORS OF INFLAMMATION>>, 2014; 2014 (N/A): 236060-N/A. [doi:10.1155/2014/236060] [http://hdl.handle.net/10807/214089]

Immunologic biomarkers for clinical and therapeutic management of psoriasis

Chiricozzi, A;
2014

Abstract

Background. The therapeutic management of psoriasis includes conventional treatments as well as the new generation of highly effective TNF-alpha inhibitors. However, psoriasis has proven to be a complex therapeutic challenge and treatment failures are not uncommon. Thus, laboratory biomarkers of disease progression/therapeutic efficacy may greatly help in the clinical management of psoriasis. Aims. To identify laboratory biomarkers for clinical management and therapeutic monitoring of psoriasis. Methods. An observational study performed on 59 patients, presenting moderate to severe psoriasis, undergoing treatment with anti-TNF-alpha agents (etanercept, adalimumab, and infliximab). Soluble and cellular immune/inflammatory parameters were assessed at baseline and after 12 and 24 weeks of treatment. Results. Clinical efficacy was achieved in 88% of the subjects at 12 weeks, reaching 90% after 24 weeks. IL-6 and IL-22, which were elevated at baseline, were significantly reduced, in association with a significant decrease of CLA+ T cells and an increase of Treg lymphocytes. T, B, and NK cell subsets and T cell response to recall antigens did not show any evidence of immune suppression. Conclusions. Immune/inflammatory parameters including IL-6 and IL-22, CLA+ T cells, and Treg lymphocytes may prove to be valuable laboratory tools for the clinical and therapeutic monitoring of psoriasis.
Inglese
Cordiali-fei, P., Bianchi, L., Bonifati, C., Trento, E., Ruzzetti, M., Francesconi, F., Bultrini, S., D'agosto, G., Bordignon, V., Francavilla, V., Tripiciano, A., Chiricozzi, A., Campione, E., Cavallotti, C., Orlandi, A., Berardesca, E., Di Carlo, A., Chimenti, S., Ensoli, F., Immunologic biomarkers for clinical and therapeutic management of psoriasis, <<MEDIATORS OF INFLAMMATION>>, 2014; 2014 (N/A): 236060-N/A. [doi:10.1155/2014/236060] [http://hdl.handle.net/10807/214089]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/214089
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 14
social impact